RxDoctor Payments Data

Miriam Brandon, MD

Internal Medicine · Powell, TNNPI 1376587790

Payments from drug & device makers

$1,210in general payments, 2019–2025

Across 58 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$241
  • Novo Nordisk$239
  • AbbVie$199
  • Galderma Laboratories, L.p.$112
  • Novartis$110
  • Astellas Pharma US Inc$72
  • plus $237 from 12 others

What the payments were for

  • Food & beverage$1,210100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,210 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$178,899
Medicare patients
275
Services billed
5,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$119,956
EliquisApixaban56$63,973
Tresiba Flextouch U-200Insulin Degludec24$55,992
TrulicityDulaglutide41$52,748
MounjaroTirzepatide32$39,100
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$38,832
JardianceEmpagliflozin41$38,036
WegovySemaglutide24$31,176
Tresiba Flextouch U-100Insulin Degludec23$25,699
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$21,025
ShingrixVaricella-Zoster Ge/As01b/Pf85$19,324
JanuviaSitagliptin Phosphate12$18,318
ArexvyRsvpref3 Antigen/As01e/Pf55$17,990
XareltoRivaroxaban31$16,603
GemtesaVibegron12$5,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$239$151,132122 claims
Lilly USA, LLCTrulicity, Mounjaro$17$91,84873 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$241$76,146188 claims
PfizerEliquis$18$63,97356 claims
Johnson & JohnsonXarelto$11$16,60331 claims
AbbVieSynthroid$199$3,06984 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Powell

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →